Several retrospective studies showed that patients with KRAS and STK11 mutations have shorter overall survival (OS) and progression-free survival (PFS) than those without these co-mutations.53–56 Similarly, the KEAP1 co-mutation was also related to worse PFS and OS in KRASm NSCLC patients.34,54,55,57 The adverse prognostic roles of STK11 and KEAP1 co-mutations might be related to lower PD-L1 expression. Here, KRAS is linked to non-small cell lung carcinoma.